News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
423,246 Results
Type
Article (26264)
Company Profile (59)
Press Release (396920)
Multimedia
Podcasts (82)
Webinars (15)
Section
Business (109295)
Career Advice (966)
Deals (22549)
Drug Delivery (112)
Drug Development (53421)
Employer Resources (86)
FDA (12635)
Job Trends (10492)
News (205517)
Policy (25886)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (3)
Academia (1841)
Accelerated approval (49)
ADA (32)
Adcomms (19)
Allergies (155)
Alliances (28489)
ALS (149)
Alzheimer's disease (1203)
Antibody-drug conjugate (ADC) (260)
Approvals (12951)
Artificial intelligence (414)
ASCO (173)
Autoimmune disease (201)
Automation (30)
Bankruptcy (227)
Best Places to Work (8227)
BIOSECURE Act (19)
Biosimilars (177)
Biotechnology (33)
Bladder cancer (134)
Brain cancer (41)
Breast cancer (530)
Cancer (3906)
Cardiovascular disease (398)
Career advice (824)
Career pathing (18)
CAR-T (203)
CDC (58)
Celiac Disease (2)
Cell therapy (567)
Cervical cancer (41)
Clinical research (48119)
Collaboration (1260)
Company closure (2)
Compensation (906)
Complete response letters (84)
COVID-19 (2213)
CRISPR (74)
C-suite (640)
Cystic fibrosis (101)
Data (6000)
Decentralized trials (2)
Denatured (17)
Depression (131)
Dermatology (71)
Diabetes (478)
Diagnostics (4505)
Digital health (35)
Diversity (8)
Diversity, equity & inclusion (26)
Drug discovery (194)
Drug pricing (200)
Drug shortages (22)
Duchenne muscular dystrophy (234)
Earnings (46895)
Editorial (59)
Employer branding (10)
Employer resources (78)
Events (49144)
Executive appointments (624)
FDA (15810)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (14)
Frontotemporal dementia (25)
Funding (1059)
Gene editing (153)
Generative AI (30)
Gene therapy (513)
GLP-1 (826)
Government (4468)
Grass and pollen (5)
Guidances (355)
Healthcare (13156)
Hematology (138)
HIV (66)
Huntington's disease (45)
IgA nephropathy (93)
Immunology and inflammation (177)
Immuno-oncology (64)
Indications (155)
Infectious disease (2506)
Inflammatory bowel disease (130)
Inflation Reduction Act (15)
Influenza (114)
Intellectual property (224)
Interviews (157)
IPO (11664)
IRA (58)
Job creations (2448)
Job search strategy (713)
JPM (35)
Kidney cancer (14)
Labor market (76)
Layoffs (478)
Leadership (19)
Legal (5852)
Liver cancer (63)
Longevity (14)
Lung cancer (510)
Lymphoma (333)
Machine learning (37)
Management (27)
Manufacturing (790)
MASH (183)
Medical device (9274)
Medtech (9376)
Mergers & acquisitions (11830)
Metabolic disorders (1245)
mRNA (153)
Multiple sclerosis (142)
NASH (16)
Neurodegenerative disease (282)
Neuropsychiatric disorders (68)
Neuroscience (2298)
NextGen: Class of 2026 (4283)
Non-profit (3334)
Now hiring (40)
Obesity (560)
Opinion (189)
Ovarian cancer (133)
Pain (195)
Pancreatic cancer (209)
Parkinson's disease (244)
Partnered (25)
Patents (478)
Patient recruitment (512)
Peanut (62)
People (31882)
Pharmaceutical (20)
Pharmacy benefit managers (27)
Phase 1 (13207)
Phase 2 (21095)
Phase 3 (17687)
Pipeline (7046)
Policy (336)
Postmarket research (1723)
Preclinical (4808)
Press Release (36)
Prostate cancer (217)
Psychedelics (42)
Radiopharmaceuticals (197)
Rare diseases (900)
Real estate (4142)
Recruiting (34)
Regulatory (20348)
Reports (36)
Research institute (1673)
Resumes & cover letters (142)
Rett syndrome (36)
RNA editing (9)
RSV (73)
Schizophrenia (136)
Series A (142)
Series B (107)
Service/supplier (5)
Sickle cell disease (87)
Special edition (22)
Spinal muscular atrophy (139)
Sponsored (34)
Startups (1771)
State (1)
Stomach cancer (9)
Supply chain (86)
Tariffs (90)
The Weekly (64)
Vaccines (933)
Venture capital (54)
Weight loss (380)
Women's health (82)
Worklife (6)
Date
Today (74)
Last 7 days (335)
Last 30 days (1741)
Last 365 days (19650)
2026 (9894)
2025 (19389)
2024 (22395)
2023 (25116)
2022 (32539)
2021 (37067)
2020 (36919)
2019 (30874)
2018 (23673)
2017 (20318)
2016 (18683)
2015 (21766)
2014 (15804)
2013 (12503)
2012 (13545)
2011 (14240)
2010 (12190)
Location
Africa (463)
Alabama (53)
Alaska (6)
Arizona (193)
Arkansas (10)
Asia (25440)
Australia (4144)
California (8186)
Canada (2591)
China (1003)
Colorado (347)
Connecticut (425)
Delaware (302)
Europe (56158)
Florida (1311)
Georgia (327)
Hawaii (1)
Idaho (44)
Illinois (680)
India (71)
Indiana (429)
Iowa (18)
Japan (401)
Kansas (103)
Kentucky (38)
Louisiana (48)
Maine (73)
Maryland (1040)
Massachusetts (5681)
Michigan (191)
Minnesota (403)
Mississippi (5)
Missouri (119)
Montana (27)
Nebraska (15)
Nevada (98)
New Hampshire (59)
New Jersey (2677)
New Mexico (14)
New York (2394)
North Carolina (1188)
North Dakota (5)
Northern California (4137)
Ohio (295)
Oklahoma (16)
Oregon (23)
Pennsylvania (1747)
Puerto Rico (26)
Rhode Island (33)
South America (693)
South Carolina (41)
South Dakota (1)
Southern California (3286)
Tennessee (153)
Texas (1278)
United States (30205)
Utah (262)
Vermont (2)
Virginia (228)
Washington D.C. (53)
Washington State (645)
West Virginia (4)
Wisconsin (78)
Wyoming (1)
423,246 Results for "united states defense threat reduction agency dtra".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Battelle Awarded Contract to Advance US Biological Threat Reduction
February 26, 2026
·
1 min read
Business
Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever
Primmune Therapeutics today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
March 20, 2024
·
4 min read
Press Releases
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
October 17, 2024
·
7 min read
Press Releases
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
April 7, 2026
·
3 min read
Press Releases
Lupin Launches Azilsartan Medoxomil Tablets in the United States
June 18, 2026
·
1 min read
Press Releases
Medline’s Prime Vendor model expands outside the United States
June 1, 2026
·
3 min read
Bio NC
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
NightHawk Biosciences today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.
December 21, 2023
·
3 min read
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
Tonix Pharmaceuticals Holding Corp. announced it has been awarded an Other Transaction Agreement with a potential for up to $34 million over five years by the Defense Threat Reduction Agency, an agency within the U.S. Department of Defense.
July 1, 2024
·
7 min read
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.
April 28, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Lupin Announces the Approval of Dapagliflozin Tablets in the United States
April 8, 2026
·
1 min read
1 of 42,325
Next
